Climb Bio, Inc.

NasdaqGM:CLYM Stock Report

Market Cap: US$738.7m

Climb Bio Future Growth

Future criteria checks 0/6

Climb Bio's earnings are forecast to decline at 28.2% per annum while its annual revenue is expected to grow at 80.9% per year. EPS is expected to decline by 21.6% per annum.

Key information

-28.2%

Earnings growth rate

-21.59%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate80.9%
Future return on equityn/a
Analyst coverage

Good

Last updated28 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Apr 16

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway

Summary Climb Bio, Inc. maintains a Buy rating, driven by budoprutug’s strong phase 1b and long-term data in primary membranous nephropathy [pMN]. CLYM’s phase 2 PrisMN trial in pMN, with initial data expected 2H 2026, is a key catalyst; expansion into SLE and ITP offers additional upside. Budoprutug’s versatility, including a subcutaneous formulation and broad B-cell depletion, positions CLYM for competitive advantage in autoimmune disorders. With $160.7M in cash, CLYM is funded into 2028, reducing near-term dilution risk and supporting execution on multiple clinical milestones. Read the full article on Seeking Alpha
Analysis Article • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Summary Eliem Therapeutics, founded in 2019, shifted focus to autoimmune diseases with the acquisition of Tenet Medicines and its lead molecule, budoprutug. Budoprutug targets CD19-positive B cells, aiming to treat SLE, ITP, and MN by reducing pathogenic autoantibodies and improving disease symptoms. Early clinical trials for MN showed promising results, with 60% of patients achieving complete remission of proteinuria, supporting further development. Despite a decent market cap and cash reserves, ELYM's early-stage status and single-molecule focus make it a cautious watch rather than an immediate investment. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia. Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million. Read the full article on Seeking Alpha
Analysis Article • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 15

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$0.56 misses by $0.09. Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of ETX-810, the company’s current cash, cash equivalents and short- and long-term marketable securities are now expected to fund operations into 2025.
Seeking Alpha • Aug 02

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Clinical-stage biotech Eliem Therapeutics (NASDAQ:ELYM) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS). The results indicated that ETX-810 did not indicate a statistically significant separation from the placebo in the primary endpoint, according to the company. The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
Seeking Alpha • Jul 11

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

SVB Leerink on Monday cut its price target on Eliem Therapeutics (NASDAQ:ELYM) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The brokerage reiterated its Outperform rating, in-line with sell-side rating of Strong Buy. "Given the decreased bioavailability of ETX-155 observed in the phase 1b interim data readout in photosensitive epilepsy, we lowered our POS for all ETX-155 programs, which resulted in our PT moving to $9," analyst Marc Goodman wrote in a note to clients. "We still expect data from ETX-810 in lumbosacral radicular pain in Q3, although expectations are low after the failed phase 2 study in diabetic peripheral neuropathy," he added. ELYM stock, which fell as much as 5.4% on Monday, has declined 67.3% YTD.

Earnings and Revenue Growth Forecasts

NasdaqGM:CLYM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-131-144-11312
12/31/2027N/A-86-91-7814
12/31/2026N/A-63-60-6215
3/31/2026N/A-53-53-53N/A
12/31/2025N/A-60-55-54N/A
9/30/2025N/A-51-44-44N/A
6/30/2025N/A-47-40-40N/A
3/31/2025N/A-93-29-29N/A
12/31/2024N/A-74-16-16N/A
9/30/2024N/A-69-11-11N/A
6/30/2024N/A-6400N/A
3/31/2024N/A-15-7-7N/A
12/31/2023N/A-35-21-21N/A
9/30/2023N/A-39-28-28N/A
6/30/2023N/A-45-36-36N/A
3/31/2023N/A-54-42-42N/A
12/31/2022N/A-45-37-37N/A
9/30/2022N/A-48-37-37N/A
6/30/2022N/A-49-46-46N/A
3/31/2022N/A-46-40-40N/A
12/31/2021N/A-52-36-36N/A
9/30/2021N/A-57-34-34N/A
6/30/2021N/A-49-23-23N/A
3/31/2021N/A-40-19-19N/A
12/31/2020N/A-23-14-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLYM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLYM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLYM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLYM is forecast to have no revenue next year.

High Growth Revenue: CLYM is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CLYM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:25
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Climb Bio, Inc. is covered by 16 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG